SANTA CLARA, Calif., June 30, 2014 /PRNewswire/ -- Benvenue Medical, Inc., a developer of minimally invasive solutions for spine repair, today announced that Jeffrey Jones has joined the company as chief operating officer. Jones brings more than 20 years of related operations experience with both medical technology start-up and Fortune 500 companies to the newly created position.
Jones is responsible for working with the senior management team to formulate current and long range plans, objectives and policies, as well as directing the company's operations, manufacturing, development and quality departments.
"Jeff brings a wealth of experience in scaling the operations of medical device companies," said Robert Weigle, CEO of Benvenue Medical, Inc. "We're happy to have Jeff join our senior management team as we continue to drive commercialization of the Kiva® VCF Treatment System as well as our other current and future products."
Previously, Jones served as vice president of operations at Acclarent, acquired by Johnson & Johnson in January 2010, where he supported rapid sales growth and was responsible for supply chain, manufacturing operations, process engineering, materials, purchasing, facilities, and environmental health and safety. Jones has also held chief operating officer positions at a number of Bay Area medical device startups, including Polyremedy, Inc.; Reliant Technologies, Inc.; and Lumend, Inc. Earlier in his career, he served as vice president of operations for Boston Scientific Corp., after it acquired EP Technologies, where Jones also served as vice president of operations. He holds a bachelor of science in engineering from the U.S. Military Academy at West Point and a master of business administration in management from Golden Gate University, and he is Six Sigma Black Belt certified.
About Benvenue Medical, Inc.
Founded in 2004, Benvenue Medical, Inc. develops next-generation, minimally invasive expandable implants for the spine. The company is privately held and funded by InterWest Partners, Versant Ventures, DeNovo Ventures, Domain Associates and Technology Partners. Its first products are designed for the treatment of vertebral compression fractures and degenerative disc disease, which have combined revenues of $1.6 billion globally. Its premier product is the Kiva VCF Treatment System, which was cleared by the U.S. Food and Drug Administration in January 2014. For more information, visit www.benvenuemedical.com.
SOURCE Benvenue Medical, Inc.